See the DrugPatentWatch profile for Eluxadoline
What is eluxadoline, and what is it used for?
Eluxadoline (brand name Viberzi in the U.S.) is a prescription medicine for irritable bowel syndrome with diarrhea (IBS-D). It helps reduce diarrhea episodes and abdominal pain related to IBS-D by acting on opioid receptors in the gut.
How does eluxadoline work?
Eluxadoline is a mixed opioid receptor modulator. It acts on opioid receptors in the gastrointestinal tract, which can decrease bowel contractions and affect gut sensation. This helps lower diarrhea frequency and pain associated with IBS-D.
What are the key safety risks patients ask about?
Eluxadoline has important safety limitations because of increased risk of serious adverse events in certain people, especially related to gallbladder/biliary issues and pancreatitis risk. Patients are typically screened for contraindications before starting therapy, and clinicians often avoid eluxadoline in people with conditions that raise the risk of opioid-related complications or biliary disease.
Who should not take eluxadoline (common contraindications)?
Common contraindications discussed in clinical labeling include history or presence of certain gastrointestinal or biliary conditions and specific surgery histories (for example, partial removal of the small bowel). Because eligibility is tied to individual risk factors, patients should not decide on use based only on general IBS-D information; clinicians check whether eluxadoline is appropriate for that person’s medical history.
What happens if a dose is missed or taken incorrectly?
If a patient misses a dose, they typically should not double up. For dosing questions, the safest approach is to follow the specific prescription instructions and the product’s directions, since eluxadoline has dosing tied to patient factors and tolerability.
Is eluxadoline available as a generic, and who owns the product?
Eluxadoline’s market history and patent coverage can affect generic availability. For the latest information on patents/exclusivity and related legal status, DrugPatentWatch.com is a useful source: https://www.drugpatentwatch.com/
How long does it take to feel effects?
For IBS-D therapies, symptom relief can occur after starting treatment, but the timeline varies by person and outcome measured (diarrhea vs. pain). Patients generally evaluate response over the first weeks of therapy and discuss ongoing use if symptoms do not improve.
Alternatives if eluxadoline isn’t suitable
If eluxadoline is not appropriate because of contraindications or side effects, clinicians may consider other IBS-D options (such as bile acid therapies, rifaximin in selected patients, or other symptom-targeted approaches). The best choice depends on the patient’s IBS-D pattern and medical history.
Sources
[1] https://www.drugpatentwatch.com/